Early embryonic development in C. elegans requires the proper temporal and spatial activation of numerous maternally-encoded cell-fate determinants. This regulation relies on the destruction of the zinc-finger protein OMA-1 in one-cell stage. OMA-1 is abundantly expressed in oocytes and is essential for proper oogenesis. OMA-1 is rapidly degraded after fertilization in wild-type embryos, however, in
oma-1 gain-of-function (gf) allele, OMA-1 protein fails to be degraded resulting in the mis-localization of numerous maternal determinants1). We isolated several ts mutants with phenotypes similar to that of
oma-1(gf). These mutations include one allele of
cdk-1, one allele of its small binding partner
cks-1, one allele of the dyrk-family kinase
mbk-2, and two new gain-of-function (gf) alleles of the
oma-1. Previous work had implicated MBK-2 in OMA-1 destruction2), and because of their similar phenotypes, we tested whether
cdk-1,
cks-1 and
gsk-3 mutants might also exhibit defects in OMA-1 degradation. We found that OMA-1 protein persists ectopically in all of these mutants. We also found that OMA-1 is stabilized in embryos after RNAi targeting cyclin B3 (
cyb-3) and casein kinase I (
kin-19). Interestingly all three of the
oma-1(gf) alleles alter the same proline residue within a consensus MBK-2 phosphorylation site in OMA-1, raising the possibility that MBK-2 directly regulates OMA-1. Consistent with this idea, we found that MBK-2 phosphorylates OMA-1 protein in-vitro and that this phosphorylation is abolished in OMA-1(gf) mutant proteins. Furthermore, we found that CKI can also phosphorylate OMA-1, but only after pre-phosphorylation by MBK-2. Similarly, GSK-3 phosphorylates OMA-1 but only after pre-phosphorylation by both MBK-2 and CKI. Since OMA-1 destruction commences during the first mitosis of embryogenesis, we speculate that destruction may be triggered by a CDK-1/cyclin B3 complex. However, we have not detected any direct phosphorylation of OMA-1 by CDK-1 kinase. Instead we found a highly conserved CDK-1 site located in the AXIN-binding domain of GSK-3. Altering this CDK-1 site does not abolish GSK-3 auto-phosphorylation but appears to prevent phosphorylation of OMA-1, suggesting that CDK-1 may directly regulate the substrate specificity of GSK-3. 1) Lin, R. Dev. Biol. 258, 226 (2003); 2) Pellettieri et al., Dev. Cell, 5, 451 (2003)